Related Experiment Videos
Screening for hydroxychloroquine retinal toxicity: is it necessary?
C D Morsman1, S J Livesey, I M Richards
1Department of Ophthalmology, University Hospital of Wales, Cardiff.
Eye (London, England)
|January 1, 1990
Summary
This study found no evidence of retinal toxicity causing vision loss in rheumatoid arthritis patients taking hydroxychloroquine (Plaquenil) for over 18 months. Routine screening for this side effect is no longer necessary in Cardiff.
Area of Science:
- Rheumatology
- Ophthalmology
Background:
- Hydroxychloroquine (Plaquenil) is a second-line therapy for rheumatoid arthritis.
- Long-term use of hydroxychloroquine can potentially cause retinal toxicity.
- Ophthalmic examinations are typically part of patient monitoring.
Purpose of the Study:
- To assess retinal toxicity in rheumatoid arthritis patients on long-term hydroxychloroquine therapy.
- To evaluate the necessity of routine screening for hydroxychloroquine-induced retinal toxicity.
Main Methods:
- Review of 73 rheumatoid arthritis patients treated with hydroxychloroquine for over 18 months.
- Analysis of patients receiving monitored dosages and regular ophthalmic examinations.
- Comprehensive testing for retinal toxicity in patients continuing the medication.
Main Results:
- No cases of retinal toxicity causing visual loss were identified in the study cohort.
- The majority of patients on long-term hydroxychloroquine therapy showed no signs of retinal damage.
- Recent literature review supports the findings.
Conclusions:
- Routine screening for hydroxychloroquine retinal toxicity is no longer recommended for rheumatoid arthritis patients in Cardiff.
- The risk of vision-threatening retinal toxicity appears low in patients on long-term hydroxychloroquine therapy with monitoring.